Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus

Phase 1

Completed

• Conditions: Diabetes Mellitus

• Registration Number: NCT00102297
• Lead Sponsor: FibroGen

Brief Summary

The Phase 1b study is a multi-center trial designed to test the safety, tolerability, biologic activity of escalating doses of FG-3019 in up to 20 patients with type 1 or type 2 diabetes and microalbuminuria (early-stage kidney disease). Patients will receive either 3 or 10 mg/kg of FG-3019 administered every two weeks as an infusion for a total of four doses. The ability of FG-3019 to reduce the excretion of protein in the urine is being measured as a secondary endpoint.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Study First Submitted: 2005-01-26
• Study First Submitted QC: 2005-01-26
• Study First Posted: 2005-01-27
• Study Completion: 2007-06
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-10
• Last Update Posted: 2007-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Written informed consent
• Body mass index not exceeding 32.0 kg/m2
• If female, subject must meet one of the following criteria: a) surgically sterile (hysterectomy or bilateral tubal ligation) OR b) at least two years postmenopausal OR c) using a dual method of contraception and have a negative serum pregnancy test if of childbearing potential
• Diagnosis of type 1 or type 2 diabetes according to the American Diabetes Association
• Fasting plasma glucose of ≥ 126 mg/dL or current treatment with oral hypoglycemic agents or insulin
• Microalbuminuria defined as albumin to creatinine ratio in a spot collection (first void) of 30 - 300 mg/gram confirmed by two samples two to three days apart
• Serum creatinine of no more than 1.5 mg/dL for men and no more than 1.1 mg/dL for women

Exclusion Criteria

• Female subjects who are pregnant or lactating
• Non-diabetic renal disease
• History of allergic or anaphylactic reaction to human, humanized, chimeric, or murine monoclonal antibodies
• Coronary artery bypass graft surgery, myocardial infarction, cerebrovascular accident, percutaneous transluminal angioplasty, transient ischemic attack, history of unstable angina, known heart failure, uncontrolled cardiac arrhythmia, or uncontrolled hypertension within six months prior to Day 0
• Bilirubin, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) > 1.5 times the upper limit of normal
• History of cancer of any type in the past 5 years, except non- melanomatous skin cancer, localized bladder cancer, or in situ cervical cancer.
• Clinically significant and uncontrolled medical condition considered a high risk for participation in an investigational study
• Trauma or surgical procedures (including dental) within six months prior to Day 0
• Planned elective surgery during the study and for 3 months following the end of the study
• Participation in studies of investigational drugs within 6 weeks prior to first dose

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety
Tolerability
Pharmacokinetics

Secondary Outcome Measures

Name	Time	Method
Bioactivity on urinary and plasma markers

Trial Locations

Locations (5)

University of Virginia; 🇺🇸 Charlottesville, Virginia, United States

Beth Israel Deaconess Medical Center; 🇺🇸 Boston, Massachusetts, United States

Diabetes & Glandular Disease; 🇺🇸 San Antonio, Texas, United States

UCLA - LA BioMed; 🇺🇸 Los Angeles, California, United States

Radiant Research; 🇺🇸 Dallas, Texas, United States